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BCIP, 5-bromo-4-chloro-3-indolyl phosphate 
DC, dendritic cell 
DC-SIGN, dendritic cell-specific intracellular adhesion molecule 3-grabbing non-
integrin 
IECs, intestinal epithelial cells 
IFN, interferon 
IgE, immunoglobulin E 
IL, interleukin 
MALDI-TOF-MS, matrix assisted laser desorption/ionization-time of flight mass 
spectrometry 
NBT, nitroblue tetrazolium 
OCT, optimal cutting temperature 
OVA, ovalbumin 
PBS, phosphate-buffered saline 
PCA, passive cutaneous anaphylaxis 
SDS, sodium dodecyl sulfate 
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SE, standard error 
TIM-3, T-cell immunoglobulin and mucin-containing protein-3; TNP, trinitrophenyl
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CHAPTER 1 
 
General Introduction 
 
 Allergic disorders are one of the major health problems in the developed country 
[1,2]. Allergy is defined as excessive immune response against normally harmless 
substances such as food, pollen or metal. Allergy is classified into four groups from type 
I to type IV on the basis of mediators, antigen, and effector mechanism. Especially, 
patients of type I allergy are increased in the world [3]. Development of type I allergy 
starts from phagocytosis of foreign antigens such as food, pollen or dust mites by antigen-
presentation cells and presentation of the antigen to naïve T cells followed by 
differentiation of naïve T cells to Th2 cells, which produce Th2 cytokines such as 
interleukin (IL)-4 and IL-13. These cytokines induce immunoglobulin class switching to 
immunoglobulin E (IgE) in B cells [4], whereby blood IgE level is increased. Increased 
IgE binds to IgE receptors on mast cells. Subsequently, when the antigen reenters the 
body, the antigen bridges IgE molecules on mast cells and mast cells are activated. 
Activated mast cells undergo degranulation and release chemical mediators such as 
histamine followed by the production of eicosanoid and cytokine [5]. These substances 
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induce symptoms of type I allergy including itch, rhinitis, hives, or anaphylaxis. 
 Through the ages, foods have been thought to modulate immune response. 
Actually, food factors including dietary fibers [6,7], polyphenols [8], and fatty acids [9] 
have been reported to exhibit immune-modulatory effects. Notably, the gut immune 
systems are associated with food compounds (e.g. dietary polysaccharide and 
Lactobacillus) since they pass through the gut [10,11]. In addition, it has been reported 
that type I allergy is suppressed by many food factors such as flavonoid [12,13], 
polyunsaturated fatty acid [14], Lactobacillus species [15-17], and polysaccharide [18]. 
Therefore, in this study, anti-allergic effect of F-fucoidan, which is one of the dietary 
polysaccharide and well-consumed in Japan, was investigated. Fucoidan is a sulfated 
polysaccharide found in brown sea algae. Although the structure of fucoidan from 
different brown sea algae varies between species, it is mainly composed of fucose and 
sulfated fucose [19]. The structure of fucoidan is mainly consisted from α-1,3 linked 
fucose and branched at C-2 or C-4 [19]. Besides these monosaccharides, other fucoidans 
from different brown sea algae also contain specific sugars such as glucose, galactose, 
xylose and uronic acid [19]. Fucoidan has various activities such as antitumor [20] and 
anticoagulant [21,22] activities through the modulation of immune responses. Therefore, 
it was supposed that fucoidan is able to suppress allergic symptoms caused by immune 
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disorders. Although fucoidan has been reported to have anti-allergic effects [23-25], there 
are few reports on the anti-allergic mechanism when fucoidan was orally administered. 
Fucoidan shows little or no absorption from the intestine [22,26]; It was presumed that 
fucoidan exhibits diverse activities against type I allergy irrespective of the administration 
pathway. Our laboratory previously reported that dietary F-fucoidan from Saccharina 
japonica, which consists of only fucose and sulfated fucose, exhibited anti-thrombotic 
effects and was eliminated without being completely absorbed [22]. This indicated that 
F-fucoidan can show activity without being absorbed into the body. 
 This study elucidated the effect of oral intake of F-fucoidan from S. japonica on 
type I allergy and its mechanism. In Chapter 2, it was investigated whether oral 
administration of crude F-fucoidan from S. japonica inhibited mast cell activation and 
following allergic symptoms induced by the passive cutaneous anaphylaxis (PCA) 
reaction, which is a simple animal model using IgE/mast cell system, and its inhibitory 
mechanism. Crude F-fucoidan could inhibit allergic symptoms induced by the PCA 
reaction only when it was through gut. The inhibitory mechanism was dependent on 
galectin-9, which belongs to a soluble lectin family that recognizes β-galactoside and has 
recently reported to prevent IgE binding to mast cells [27]. The anti-allergic properties of 
crude F-fucoidan were cancelled by an intravenous dose of anti-galectin-9 antibody or 
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lactose, which bind competitively with galectin-9, before the PCA reaction. Moreover, 
crude F-fucoidan increased the expression level of galectin-9 mRNA in intestinal 
epithelial cells (IECs) and serum galectin-9 levels. The author demonstrated that Oral 
treatment with crude F-fucoidan suppressed allergic symptoms through the induction of 
galectin-9 in Chapter 2. Crude F-fucoidan contained three fractions. Therefore, in Chapter 
3, the active form of crude F-fucoidan was clarified. Furthermore, it was examined 
whether the effect of F-fucoidan as shown in Chaper 2 is F-fucoidan from S. japonica-
specific effect (Chapter 4). The results in Chapter 2 indicated that F-fucoidan might 
exhibit anti-allergic property even after sensitization by antigen. Therefore, in Chapter 5, 
the effect of F-fucoidan in an allergy model that allergy was induced by injection of 
allergen was demonstrated. F-fucoidan inhibited allergic symptom induced by mast cell 
activation but not polarization to Th2. These results indicated that F-fucoidan from S. 
japonica induced the expression of galectin-9 in IECs and secretion of galectin-9 into 
blood, resulting in the prevention of type I allergic symptoms by galectin-9 binding to 
IgE and preventing the interaction of IgE and mast cells. 
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CHAPTER 2 
 
Anti-Allergic Effect of F-fucoidan Contained in Saccharina japonica through 
Induction of Galectin-9 from Small Intestinal Epithelial Cells. 
 
2.1. Introduction 
 As mention in chapter 1, type I allergy is caused by the conjugation of IgE and 
mast cells and then the binding antigen to the complex of IgE and mast cell. These 
reaction are important to induce mast cell degranulation. Therefore, to investigate the 
inhibitory effect of F-fucoidan from S. japonica on mast cell activation induced by IgE, 
the author used PCA reaction model, which is known as a simple animal model of an IgE- 
and mast cell-dependent acute allergic reaction.  
 In this chapter, the mechanism of the effect of F-fucoidan was investigated after 
evaluation of the inhibitory effect of F-fucoidan on mast cell activation. Galectin-9 was 
particularly focused in this study because it was recently reported that galectin-9 
suppressed mast cell degranulation [27]. Galectin-9, one of the galectin families which is 
soluble lectin that binds β-galactoside, has been reported as one of the inhibitory factor 
of mast cell activation [27]. Although galectin-9 was originally found as a potent 
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eosinophil chemoattractant, it has complicated functions in immune modulation. For 
example, galectin-9 has been reported to exhibit divergent activities such as preventive 
effects on autoimmune disease through the suppression of Th1 and Th17 cells and the 
induction of regulatory T cells [28] and effects on enhancement antitumor immunity by 
the induction of dendritic cell (DC) maturation and the promotion of Th1 immune 
responses [29]. Some reports suggested that galectin-9 levels increase in mouse models 
of allergic airway [30], food allergy [31], and atopic dermatitis [32]. However, other 
reports indicated that exogenous galectin-9 diminished allergic inflammation in a mouse 
model of allergic asthma [33]. Moreover, galectin-9 has been reported recently to interact 
with IgE, whereby mast cell degranulation was suppressed [27]. Thus, as it was suspected 
that galectin-9 involved in the inhibitory effect of F-fucoidan on mast cell activation, the 
author examined the contribution of galectin-9 to the effect of F-fucoidan.  
 
 
2.2. Materials and Methods 
2.2.1. Materials 
Mouse anti-2,4,6-trinitrophenyl (TNP) monoclonal IgE was purchased from BD 
Biosciences (San Jose, CA, USA). 2,4,6-Trinitrochlorobenzene was purchased from 
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Tokyo Chemical Industry (Tokyo, Japan). Recombinant mouse galectin-9 was purchased 
R&D Systems (Minneapolis, MN, USA), and an anti-mouse galectin-9 antibody was 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and R&D Systems. Anti-
mouse IgE and anti-goat IgG-HRP antibodies were purchased from Bethyl Laboratories 
(Montgomery, AL, USA).  
 
2.2.2. Preparation of crude F-fucoidan 
Crude F-fucoidan was extracted from S. japonica. Powdered S. japonica was stirred in 
20 times volume of sodium acetate buffer (pH 4.6) over night. After centrifugation (3,500 
rpm, 10 min), supernatant was lyophilized. The lyophilized powder was defined crude F-
fucoidan. 
 
2.2.3. Mice 
Female BALB/c mice (4 weeks old) were purchased from Japan SLC (Shizuoka, Japan). 
Mice were housed in an air-conditioned animal room at a temperature of 23 ± 2°C and a 
humidity of 55 ± 10%. Mice were acclimatized with ad libitum supply of food and 
drinking water. This study was approved by the Institutional Animal Care and Use 
Committee and carried out according to the Kobe University Animal Experimentation 
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Regulations (permission number: 25-06-04). 
 
2.2.4. Passive cutaneous anaphylaxis reaction 
Mice were intravenously sensitized with anti-TNP IgE and then challenged with 
application of 1.6% 2,4,6-trinitrochlorobenzene in acetone:olive oil (1:1) as an antigen 
on the ear at 30 min after sensitization. Ear thickness was measured using a micrometer 
(Ozaki MFG., Tokyo, Japan) before and 2 h after antigen challenge, and the difference in 
ear thickness between before and after application of the antigen was defined as an edema. 
Before PCA reaction, mice were orally or intraperitoneally administered crude F-fucoidan 
(100, 200 or 400 μg/day) everyday for 4 days. To investigate the contribution of galectin-
9 to the anti-allergic properties of F-fucoidan, mice were injected intravenously with an 
anti-galectin-9 antibody (50 μg) 1 h before the PCA reaction. To evaluate whether 
galectin-9 induced by F-fucoidan prevented type I allergy through binding IgE, mice were 
injected intravenously with lactose (100 mM) 10 min before the PCA reaction. Sucrose 
was used as a negative control in the same manners. 
 
2.2.5. Sampling of tissues, RNA isolation and real-time PCR 
Ears were collected after PCA reaction and homogenized using Multi-beads shocker 
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(Yasui Kikai, Osaka, Japan) to measure expression of IL-4 mRNA. Harvested ileum was 
washed in ice-cold phosphate-buffered saline (PBS) to remove feces and then cut 
longitudinally. IECs were isolated by scraping using a glass slide. Total RNA was 
extracted from the tissues using Sepasol RNA I super G (Nacalai Tesque, Kyoto, Japan) 
in accordance with the manufacturer’s protocol. cDNA synthesis was performed using a 
High-Capacity cDNA Reverse Transcription kit (Life Technologies, Carlsbad, CA, USA). 
Quantitative PCR was performed using a 7500 Fast Real Time PCR system (Life 
Technologies) using TaqMan® Fast Universal PCR Master Mix (Life Technologies), and 
Gene Expression Assays for mouse IL-4, galectin-9 and β-actin (Life Technologies), in 
accordance with the manufacturer’s protocol. 
 
2.2.6. Histological analysis 
Ears were fixed in 4% (v/v) paraformaldehyde, embedded in optimal cutting temperature 
(OCT) compound (Sakura Finetek Japan, Tokyo, Japan) and cut using a microtome. The 
sections (4 μm thickness) were stained with 0.001% toluidine blue (pH 2.5) for 4 h to 
detect of granule of mast cells.  
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2.2.7. Immunoprecipitation, SDS-PAGE and Western blotting for detection of galectin-9 
Recombinant mouse galectin-9 (250 ng) and lactose (100 mM) were mixed and left on 
ice for 15 min. Sucrose (100 mM) was used as a negative control. Anti-TNP IgE (50 ng) 
was added to each mixture solution and left on ice for additional 15 min. The mixtures 
were incubated with anti-mouse IgE antibodies bound to protein G Dynabeads (Life 
Technologies) at room temperature for 10 min. After Dynabeads were magnetically 
precipitated, sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl (pH 6.8), 
1% SDS, 10% glycerol, 0.005% bromophenol blue, and 0.2 M 2-mercaptoethanol) was 
added to both of the supernatants and the precipitates, and then heated at 70°C for 10 min. 
Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto polyvinylidene fluoride membranes (General Electric, Fairfield, CT, 
USA). Anti-mouse galectin-9 or anti-mouse IgE antibodies were reacted as the primary 
antibody at 4°C overnight, followed by anti-goat IgG-HRP antibody as the secondary 
antibody at 4°C for 1 h. All signals were detected by enhanced chemiluminescence using 
Chemi-Lumi One (Nacalai Tesque). In the case of detection of galectin-9 in serum, SDS-
PAGE and Western blotting were conducted using 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP)/ nitroblue tetrazolium (NBT) Phosphatase Substrate and PhosphaGLO Reserve
™ AP Substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) instead of 
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Chemi-Lumi One. 
 
2.2.8. In-gel digestion and mass spectrometric analysis 
The band after SDS-PAGE was digested by trypsin and then the digested sample was 
analyzed in matrix assisted laser desorption/ionization-time of flight-mass spectrometry 
(MALDI-TOF-MS). Protein was identified using MASCOT (Matrix Science). 
 
2.2.9. Statistical analysis 
Data were expressed as means ± the SE. Statistical analysis was performed by Tukey-
Kramer test. p < 0.05 was considered statistically significant. 
 
 
2.3. Results 
2.3.1. Effect of F-fucoidan on passive cutaneous anaphylaxis reaction 
To investigate whether oral administration of F-fucoidan could inhibit a type I allergic 
reaction, PCA reaction was conducted after oral administration of crude F-fucoidan. Oral 
administration of crude F-fucoidan prevented ear edema induced by IgE/antigen at a 
concentration of more than 200 μg/day (Fig. 2.1.A). Moreover, oral administration of  
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Figure 2.1. Effect of F-fucoidan on ear edema induced by the passive cutaneous 
anaphylaxis reaction. 
Mice were administered crude F-fucoidan orally (100, 200, or 400 𝜇g/day) for 4 days 
and conducted a passive cutaneous anaphylaxis (PCA) reaction. (A) Ear edema was 
evaluated 2 h after antigen (Ag) challenge. (B) Ears were collected after PCA reaction 
and ear-skin frozen sections (4 𝜇m) were stained by toluidine blue. Boxed areas in upper 
side (scale bar, 50 𝜇m) are magnified below (scale bar, 25 𝜇m). Allows and allowheads 
indicates rest mast cell and degranulated mast cell, respectively. (C) IL-4 mRNA 
expression in ears after PCA reaction was measured. * p < 0.05, significantly different 
from the values of the group that did not receive crude F-fucoidan. ** p < 0.01. Values 
represent the means ± S.E. of 3 mice in each group. 
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crude F-fucoidan inhibited mast cell degranulation (Fig. 2.1.B) and following expression 
of IL-4 mRNA (Fig. 2.1.C). Many previous studies have indicated that fucoidan exhibited 
anti-allergic effect when fucoidan was intraperitoneally administrated [24,25]. Therefore, 
to investigate whether only oral administration of crude F-fucoidan can prevent ear edema 
induced by IgE/antigen, mice were intraperitoneally administrated crude F-fucoidan and 
tested PCA reaction. As a result, F-fucoidan exhibited inhibitory effect on mast cell 
activation only when F-fucoidan was administrated orally but not intraperitoneally (Fig. 
2.2). These data suggested that F-fucoidan shows an inhibitory effect on type I allergy 
only the through gut. 
 
Figure 2.2. Difference in the pathway of 
administration of F-fucoidan. 
Mice were orally (p.o.) or 
intraperitoneally (i.p.) administered 
crude F-fucoidan (200 𝜇g/day) for 4 
days and induced allergic symptom 
by passive cutaneous anaphylaxis 
reaction. Ear edema was evaluated 2 
h after antigen (Ag) challenge. ∗ p < 
0.05. Values represent the means ± 
S.E. of 3 mice in each group. 
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2.3.2. Galectin-9 content in blood of mice administered F-fucoidan 
It has been reported that galectin-9 prevents mast cell degranulation and ear edema 
induced by PCA reaction through an interaction with IgE [27]. Therefore, to investigate 
the function of galectin-9 in the inhibitory effect of F-fucoidan on the PCA reaction, 
galectin-9 in the blood of mice administered F-fucoidan was detected by Western blotting. 
As shown the typical result in Fig. 2.3, a band corresponding to the molecular weight of 
galectin-9 was detected in serum of mice administered F-fucoidan. To confirm the identity 
of this band, the band after SDS-PAGE was analyzed in MALDI-TOF-MS. As a result, 
sequence of the band matched with the sequence of mouse galectin-9 at score of 318. It 
was demonstrated that the oral administration of crude F-fucoidan increased galectin-9 
content in the blood. 
 
 
Figure 2.3. Increase in galectin-9 in serum of mice administered F-fucoidan. 
Mice were administered crude F-fucoidan orally (200 𝜇g/day) and blood was collected. 
Galectin-9 in serum was detected using an anti-mouse galectin-9 antibody. 
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2.3.3. Association between suppression of the passive cutaneous anaphylaxis reaction 
and galectin-9 induction by oral administration of F-fucoidan 
It has been reported that high expression levels of galectin-9 in the intestine led to the 
suppression of food allergy [34]. Therefore, to examine whether expression of galectin-9 
in the intestine was increased when mice were orally administered F-fucoidan, galectin-
9 mRNA expression levels in IECs of mice administered F-fucoidan were measured. 
Galectin-9 mRNA expression levels did not show any change in response to IgE/antigen 
challenge compared with just an antigen challenge (Fig. 2.4.A). However, in the group 
administered crude F-fucoidan, the expression level of galectin-9 mRNA was 
significantly increased (Fig. 2.4.A). To examine the requirement for galectin-9 in the anti-
allergic properties of F-fucoidan, an anti-galectin-9 antibody were intravenously injected 
1 h before the PCA reaction in mice with an oral administration of crude F-fucoidan. As 
shown in Fig. 2.4.B, ear edema which was suppressed by oral administration of F-
fucoidan were completely canceled by intravenous injection of the anti-galectin-9 
antibody. 
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Figure 2.4. Involvement of galectin-9 in the inhibitory effect of F-fucoidan on type I 
allergy. 
(A) Mice were administered crude F-fucoidan orally (200 𝜇g/day) for 4 days and induced 
allergic symptoms by passive cutaneous anaphylaxis (PCA) reaction. Galectin-9 mRNA 
expression in intestinal epithelial cells after PCA reaction was measured. (B) Mice were 
administered crude F-fucoidan orally (200 𝜇g/day) for 4 days and intravenously injected 
with anti-galectin-9 antibody (Ab) or isotype IgG 1 h before PCA reaction. Ear edema 
was evaluated 2 h after the antigen (Ag) challenge. ∗ p < 0.05, ∗∗ p < 0.01. Values 
represent the means ± S.E. of 3 mice in each group. 
 
 
2.3.4. Binding between galectin-9 and IgE in the inhibitory properties of F-fucoidan in 
the passive cutaneous anaphylaxis reaction 
It has been reported that the interaction of galectin-9 with IgE was competitively inhibited 
by lactose [27]. Indeed, lactose inhibited co-immunoprecipitation of galectin-9 with IgE 
in vitro and galectin-9 was detected in the supernatant, but sucrose did not (Fig. 2.5.A).  
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Figure 2.5. Lactose-mediated inhibition of the interaction between galectin-9 and 
IgE and the effect of F-fucoidan on ear edema induced by IgE/antigen. 
(A) IgE and galectin-9 reacted with or without lactose, followed by immunoprecipitation 
with an anti-mouse IgE antibody and Western blotting with an anti-mouse galectin-9 
antibody. The data are representative of triplicate experiments. (B) Mice were 
administered crude F-fucoidan orally (200 𝜇g/day) for 4 days and intravenously injected 
with lactose or sucrose 10 min before passive cutaneous anaphylaxis reaction. Ear edema 
measured 2 h after antigen (Ag) challenge. ∗ p < 0.05, ∗∗ p < 0.01. Values represent the 
means ± S.E. of 3 mice in each group. 
 
To confirm the effect of lactose in vivo, mice administered crude F-fucoidan were 
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intravenously injected lactose. As shown in Fig. 2.5.B, ear edema was recovered by the 
intravenous administration of lactose to equal levels to mice challenged with IgE/antigen 
despite of oral administration of crude F-fucoidan. However, in mice administered 
sucrose which did not contain galactose, ear edema was suppressed to the same level as 
mice administered crude F-fucoidan. These data indicated that oral treatment with F-
fucoidan might increase galectin-9 content in the blood and induced galectin-9 prevents 
the interaction of IgE and mast cells. 
 
 
2.4. Discussion 
 In previous reports on the anti-allergic effects of fucoidan, it inhibits allergic 
symptoms through modulating the polarized immune response and inhibiting the 
production of IgE [25,35]. Briefly, fucoidan has been thought to mainly exert an 
inhibitory effect on allergy by modulation of the Th1/Th2 balance. However, in this study, 
F-fucoidan inhibited mast cell activation followed by ear edema formation, which was 
caused by mast cell degranulation. (Fig. 2.1). This anti-allergic mechanism of F-fucoidan 
is a novel and different mechanism from that was previously reported as an effect of 
fucoidan. 
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In this study, intravenous administration of an anti-galectin-9 antibody prevented 
the inhibitory effect of F-fucoidan on ear edema (Fig. 2.4.B). It was ascertained that the 
inhibitory effect of F-fucoidan on ear edema induced by IgE/antigen reaction depended 
on galectin-9. Galectin-9 possesses the high affinity to IgE and prevents binding of IgE 
to IgE receptor FcεRI, resulting in the inhibition of mast cell activation [27]. Moreover, 
administration of F-fucoidan increased the expression level of the galectin-9 mRNA in 
IECs (Fig. 2.4.A) and the content of galectin-9 in serum (Fig. 2.3). The inhibitory effect 
of F-fucoidan on ear edema was shown only when F-fucoidan was administered orally 
(Fig. 2.2). Taking into consideration these results, it was predicated that oral 
administration of F-fucoidan influenced IECs and promoted the expression and secretion 
of galectin-9 into blood. As shown in Fig. 2.5, the inhibitory effect of F-fucoidan on ear 
edema was also prevented by intravenous administration of lactose, which galectin-9 and 
suppresses the interaction of galectin-9 with IgE [27]. These results suggested that 
secreted galectin-9 by F-fucoidan bound to IgE in blood and prevented ear edema. 
Galectin-9 has been reported to have the inhibitory properties against allergy 
[27,33,36] and various autoimmune diseases [28,37-39]. However, in these studies mice 
were administered exogenous galectin-9 or overexpressed galectin-9. The substances that 
can induce galectin-9 are less understood, although there was a report that combination 
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of oligosaccharides in human milk with bifidobacteria can increase galectin-9 in IECs 
and blood, whereby food allergy was suppressed [34]. In this study, we demonstrated that 
F-fucoidan from S. japonica possessed an ability to increase expression of galectin-9 in 
IECs (Fig. 2.4.A). Furthermore, administration of F-fucoidan increased the amounts of 
galectin-9 in blood (Fig. 2.3). These data indicated that F-fucoidan is a novel inducer of 
galectin-9. Moreover, the inhibitory effect of F-fucoidan on type I allergy through the 
induction of galectin-9 was observed only when F-fucoidan was administered orally (Fig. 
2.2). This suggested that dietary intake of S. japonica could be useful for the induction of 
galectin-9, followed by preventive effects on allergic symptoms. 
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CHAPTER 3 
 
Identification of the Active Form of F-fucoidan from S. japonica. 
 
3.1. Introduction 
 In Chapter 2, the author exhibited that crude F-fucoidan from S. japonica has 
anti-allergic effect due to induction of galectin-9. However, crude F-fucoidan included 
not only F-fucoidan but also alginic acid [22,40]. Alginic acid is a polysaccharide and 
consisted of β-D-mannuronic acid and α-L-guluronic acid [41]. Alginic acid has been 
reported to exhibit anti-allergic effect through the suppression of mast cell activation [42] 
and the inhibition of IgE production [43]. Therefore, the author thought that the effect of 
crude F-fucoidan in Chapter 2 might be due to alginic acid. Furthermore, it was reported 
that crude F-fucoidan includes fucoidan of various molecular weights [22]. In this chapter, 
the author investigated which polysaccharide possessed the activity in crude F-fucoidan. 
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3.2. Materials and Methods 
3.2.1. Reagents 
Mouse anti-2,4,6-trinitrophenyl (TNP) monoclonal IgE was purchased from BD 
Biosciences (San Jose, CA, USA). 2,4,6-trinitrochlorobenzene was purchased from 
Tokyo Chemical Industry (Tokyo, Japan). 0.5% (w/v) Methyl cellulose was purchased 
from Wako Pure Chemical Industries (Osaka, Japan). 
 
3.2.2. Preparation of high and low molecular weight of F-fucoidan and alginic acid 
Crude F-fucoidan was prepared as described in Chapter 2. Then, crude F-fucoidan was 
dissolved in distilled water and applied to a Toyopearl-DEAE 650M column (2.0 × 20 
cm; TOSOH, Tokyo, Japan). The each fraction was eluted by stepwise gradient of 0.5M 
and 1.0 M NaCl.  
 
3.2.3. Passive cutaneous anaphylaxis reaction 
Mice were purchased and preliminary bred as described in Chapter 2. The PCA reaction 
was conducted as described in Chapter 2. Before the PCA reaction, mice were orally 
administered each fraction prepared in section 3.2.2. with ratio of recovery weight from 
crude F-fucoidan everyday for 4 days. To investigate the influence of viscosity of crude 
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F-fucoidan, 100 μl of 0.5% (w/v) methyl cellulose was administered for 4 days before the 
PCA reaction. 
 
3.2.4. Sampling of tissues, RNA isolation and real-time PCR 
IECs were prepared and the expression of galectin-9 and β-actin in IECs was measured 
as described in Chapter 2. 
 
3.2.5. Statistical analysis 
Data were expressed as means ± the SE. Statistical analysis was performed by Tukey-
Kramer test. p ˂ 0.05 was considered statistically significant. 
 
 
3.3. Results  
3.3.1. Isolation of the fraction in crude F-fucoidan 
In ion-exchange chromatography, three main peaks were observed. The first fraction was 
non-absorbed fraction on the column and this fraction was identified as high molecular 
weight (30 to 50 kDa) of F-fucoidan. The fraction eluted with 0.5 M NaCl was identified 
as alginic acid. The fraction eluted with 1.0 M NaCl was identified as low molecular 
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weight (less than 20 kDa) of F-fucoidan (Fig. 3.1). Crude F-fucoidan contained high and 
low molecular weight of F-fucoidan and alginic acid at a ratio of 30%, 30%, and 23%, 
respectively. 
 
 
Figure 3.1. Separation of crude F-fucoidan. 
Powdered S. japonica was stirred in 20 times volume of sodium acetate buffer (pH 4.6) 
over night. Then, crude F-fucoidan was applied to a Toyopearl-DEAE 650M column (2.0 
× 20 cm). The fraction not adsorbed by the column was identified as high molecular 
weight of F-fucoidan. The fraction eluted with 0.5 M NaCl was alginic acid and the 
fraction eluted with 1.0 M NaCl was identified as low molecular weight of F-fucoidan.  
 
3.3.2. Identification of the active polysaccharides in crude F-fucoidan on mast cell 
activation 
To identify the active polysaccharides in crude F-fucoidan, mice were administrated three 
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fractions at the dose corresponding to weigh ratio of crude F-fucoidan (200 μg/day), high 
and low molecular weight of F-fucoidan (60 μg/day, respectively), or alginic acid (46 
μg/day), and tested the PCA reaction. As shown in Fig. 3.2.A, high molecular weight of 
F-fucoidan prevented ear edema induced by IgE/antigen. In contrast, low molecular 
weight of F-fucoidan or alginic acid did not inhibit ear edema. Especially, alginic acid did 
not prevent ear edema at all. It was understood that high molecular weight of F-fucoidan 
was unstable at more than 50°C and changed to low molecular weight of F-fucoidan. To 
confirm whether the heat degradation of high molecular weight of F-fucoidan affected 
the inhibitory effect on ear edema, mice were orally administrated high molecular weight 
of F-fucoidan heated at 50°C for 10 min and tested the PCA reaction. The heat 
degradation of high molecular weight of F-fucoidan did not inhibit ear edema (Fig. 3.2.A). 
This suggested that high molecular weight of F-fucoidan per se exhibit the inhibitory 
effect on ear edema induced by mast cell activation. Moreover, as it was demonstrated 
that the inhibitory effect of crude F-fucoidan on mast cell was due to induction of galectin-
9 in Chapter 2, the expression of galectin-9 in IECs from mice administrated each fraction 
in crude F-fucoidan was measured. In IECs from mice administrated crude or high 
molecular weight of F-fucoidan, galectin-9 mRNA expression was increased, whereas 
low molecular weight of F-fucoidan and alginic acid did not affect the expression 
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Figure 3.2. The effect of the fractions in crude F-fucoidan on ear edema induced by 
the passive cutaneous anaphylaxis reaction and galectin-9 mRNA expression. 
Mice were administered crude F-fucoidan, high and low molecular weight of F-fucoidan, 
or alginic acid orally (200, 60, 60, 46 𝜇g/day, respectively) for 4 days and tested for the 
passive cutaneous anaphylaxis (PCA) reaction. (A) Ear edema was evaluated 2 h after the 
antigen (Ag) challenge. (B) Galectin-9 mRNA expression in intestinal epithelial cells 
after PCA reaction was measured. Different alphabet indicates a significant difference. 
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of galectin-9 mRNA (Fig. 3.2.B). This result was similar to the result of ear edema. 
Therefore, it was considered that the active form of crude F-fucoidan, which exhibited 
the inhibitory effect on mast cell activation through galectin-9 induction, was high 
molecular weight of F-fucoidan. 
 
3.3.3. The contribution of viscosity in crude F-fucoidan to the inhibitory effect on mast 
cell activation 
Fractions of crude and high molecular weight of F-fucoidan, which exhibited the 
inhibitory effect on mast cell activation, have viscosity. The heat degradation of high 
molecular weight of F-fucoidan which did not inhibit ear edema in section 3.3.2. lost 
viscosity. Moreover, it has been reported that high viscous polysaccharide from 
Kjellmaniella crassifolia could modulate immune responses [44]. To examine whether 
the effect of F-fucoidan on ear edema induced by IgE/antigen was dependent on viscosity 
or molecular weight, mice were administered methyl cellulose which is hydrosoluble 
polysaccharide and has viscosity, and conducted the PCA reaction. Ear edema in mice 
administered methyl cellulose was no change compared with that in mice stimulated by 
IgE/antigen (Fig. 3.3). This result suggested that crude and high molecular weight of F-
fucoidan exhibited the inhibitory effect on mast cell activation regardless of the viscosity. 
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Figure 3.3. The inhibitory effect of viscosity on ear edema induced by the passive 
cutaneous anaphylaxis reaction. 
Mice were administered crude F-fucoidan (200 𝜇g/day), or 100 𝜇l of 0.5% (w/v) methyl 
cellulose was administered for 4 days and tested for the passive cutaneous anaphylaxis 
reaction. Ear edema was evaluated 2 h after the antigen (Ag) challenge. ∗ p < 0.05. Values 
represent the means ± S.E. of 3 mice in each group. 
 
 
3.4. Discussion 
 Crude F-fucoidan was divided into three fractions of high and low molecular 
weight of F-fucoidan and alginic acid in DEAE-chromatography. Although the crude F-
fucoidan possessed the inhibitory effect on mast cell activation by secretion of galectin-9 
as shown in Chapter 2, it was not clarified which fractions of crude F-fucoidan exerted 
the effect. Therefore, each fraction was administrated at the dose contained in effective 
amount of crude F-fucoidan (200 μg/day) and conducted the PCA reaction. It was 
revealed that only high molecular weight of F-fucoidan can inhibit ear edema and increase 
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expression of galectin-9 mRNA in IECs (Fig. 3.2). Low molecular weight of F-fucoidan 
might inhibit ear edema if it was carried out at higher dose, because it was seemed that 
low molecular weight of F-fucoidan slightly inhibit ear edema (Fig. 3.2.A). However, 
only high molecular weight of F-fucoidan could inhibit ear edema and increase galectin-
9 mRNA expression at the dose contained in effective amount of crude F-fucoidan. 
Therefore, it was eliminated that low molecular weight of F-fucoidan inhibited by the 
different mechanism with crude and high molecular weight of F-fucoidan if low 
molecular weight of F-fucoidan at more dose can inhibit ear edema. 
In this study, alginic acid did not inhibit ear edema in contradiction to previous 
reports that alginic acid has anti-allergic effects [42,43]. Mice were administered alginic 
acid at considerably less dose, 2.3 mg/kg body weight, compared with previous reports 
that alginic acid was administered at 0.5-1 g/kg body weight. Therefore, it was presumed 
that alginic acid cannot inhibit ear edema in this study. 
In this chapter, the author identified the active form possessing the inhibitory 
effect on mast cell activation as a high molecular weight fraction in crude F-fucoidan. 
Moreover, the effect of F-fucoidan was not due to viscosity but molecular weight. 
Therefore, it was demonstrated the caution that S. japonica should cook less than at 50oC 
to exert its anti-allergic activity.  
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CHAPTER 4 
 
Inhibitory Effects of Fucoidan from Various Brown Sea Algae on Mast Cell 
Activation. 
 
4.1. Introduction 
 In Chapter 2 and 3, the author showed the anti-allergic mechanism and the active 
form of fucoidan from S. japonica. However, it is well-known that fucoidan is contained 
in various brown sea algae such as Kombu, Wakame, and Hijiki [45], and fucoidan from 
various sea algae has been reported to possess anti-allergic effect. For example, fucoidan 
from Undaria pinnatifida sporophylls suppressed Th2 immune response [46], and 
fucoidan from Fucus vesiculosus inhibited ear swelling induced by contact 
hypersensitivity [47]. Although administration of fucoidan in these reports was 
intraperitoneally injection, fucoidan from various sea algae has possibility having the 
inhibitory effect on ear edema induced by IgE/antigen even with oral administration. In 
this chapter, the author investigated whether the inhibitory effect of fucoidan from S. 
japonica on mast cell activation was specific. 
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4.2. Materials and Methods 
4.2.1. Preparation of crude F-fucoidan from brown sea algae 
Crude F-fucoidan was prepared from Makombu (S. japonica), Gagome Kombu 
(Saccharina sculpera), Rishiri Kombu (variant species of S. japonica), Rausu Kombu 
(variant species of S. japonica), Naga Kombu (Saccharina longissima), Hidaka Kombu 
(Saccharina angustata), Atsuba Kombu (Saccharina coriacea), or Okinawa Mozuku 
(Cladosiphon okamuranus Tokida) by the same methods as described in Chapter 2.  
 
4.2.2. Passive cutaneous anaphylaxis reaction 
Mice were purchased and preliminary bred as described in Chapter 2. The PCA reaction 
was conducted as described in Chapter 2. Before the PCA reaction, mice were orally 
administered crude F-fucoidan from above brown sea algae (200 μg/day) everyday for 4 
days. 
 
4.2.3. Statistical analysis 
Data were expressed as means ± the SE. Statistical analysis was performed by Tukey-
Kramer test. p ˂ 0.05 was considered statistically significant. 
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4.3. Results  
4.3.1. Yield of fucoidan from various sea algae 
Yield of crude fucoidan from various sea algae was described in table 4.1. The algae 
which contained the most amount of fucoidan was Atsuba Kombu and the algae which 
contained the fewest amount of fucoidan was Okinawa Mozuku. Surprisingly, Gagome 
Kombu contained different amount of fucoidan depending on origins. 
 
Table 4.1. Yield of fucoidan from varions brown sea algae 
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4.3.2. Inhibitory effect of fucoidan from various sea algae on ear edema induced by 
IgE/antigen 
To investigate whether fucoidan fraction extracted from various algae possessed the 
inhibitory effect on mast cell activation, mice were administered 200 𝜇g/day of crude 
fucoidan from various sea algae for 4 days and tested the PCA reaction. Fucoidan from 
other sea algae did not inhibit ear edema at all (Fig. 4.1).  
 
 
Figure 4.1. The inhibitory effect of fucoidan from various sea algae on ear edema 
induced by the passive cutaneous anaphylaxis reaction. 
Mice were administered crude fucoidan from Makombu (S. japonica), Gagome Kombu 
(Saccharina sculpera), Rishiri Kombu (variant species of S. japonica), Rausu Kombu 
(variant species of S. japonica), Naga Kombu (Saccharina longissima), Hidaka Kombu 
(Saccharina angustata), Atsuba Kombu (Saccharina coriacea), or Okinawa Mozuku 
(Cladosiphon okamuranus Tokida) orally and tested for the passive cutaneous 
anaphylaxis reaction. Ear edema was evaluated 2 h after the antigen challenge. * p < 0.05, 
significantly different from the values of the group that did not receive crude fucoidan. 
Values represent the means ± S.E. of 3 mice in each group. 
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4.4. Discussion 
It has been reported that the structure of fucoidan varies from species of brown 
sea algae [19]. For example, it was clarified that fucoidan contained in S. japonica is 
consisted of only fucose and sulfated fucose, and that in C. okamuranus Tokida is 
consisted of fucose, sulfated fucose and glucuronic acid [48]. Therefore, it was 
investigated whether the anti-allergic property of F-fucoidan from S. japonica shown in 
Chapter 2 was F-fucoidan-specific one. Generally, it has been known that Rishiri and 
Rausu Kombu are variant species of S. japonica. Thus, the author speculated that fucoidan 
from Rishiri and Rausu Kombu could inhibit ear edema induced by IgE/antigen. 
Unexpectedly, any fucoidan from sea algae except for Makombu (S. japonica) could not 
affect ear edema induced by IgE/antigen (Fig. 4.1). This suggested that the inhibitory 
effect of fucoidan on mast cell activation was fucoidan from S. japonica-specific effect. 
It was clarified that only fucoidan consisted of fucose and sulfated fucose could exhibit 
anti-allergic effect with the induction of galectin-9 secretion. 
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CHAPTER 5 
 
The Immune-Modulatory Effect of F-fucoidan from S. japonica. 
 
5.1. Introduction 
 In Chapter 2, the author demonstrated that F-fucoidan from S. japonica 
possessed anti-allergic effect by inhibition of mast cell activation through induction of 
galectin-9 which possessed the high affinity to mast cells. This was predicted that F-
fucoidan might exhibit anti-allergic effect even after sensitization by antigen. To confirm 
this hypothesis, ovalbumin (OVA)-induced allergy model was used. OVA has been 
commonly used as experimental antigen for induction of type I allergy [49-51]. 
Administration of OVA as antigen allows observation of allergy from sensitization to 
pathogenesis. The author evaluated the effect of F-fucoidan on deflection to Th2 by 
measuring serum contents of IgE and IgG1, and cytokine production after stimulation by 
OVA. The effect of F-fucoidan on mast cell activation was estimated by measurement of 
rectal temperature as severity of allergy after stimulation by OVA because it seems to be 
difficult to detect the allergy symptom in the increase of IgE contents in blood. 
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5.2. Materials and Methods 
5.2.1. Reagents 
OVA and Al(OH)3 were purchased from Sigma-Aldrich (Saint Louis, MO, USA). 
 
5.2.2. Preparation of crude and high molecular weight of F-fucoidan 
Crude and high molecular weight of F-fucoidan were prepared as described in Chapter 2 
and 3. 
 
5.2.3. Ovalbumin-induced allergy model 
Mice were purchased and preliminary bred as described in Chapter 2. Mice were 
sensitized by intraperitoneal injection of 300 μl PBS containing 10 μg OVA mixed with 
1 mg Al(OH)3 adjuvant and boosted by injection of 10 μg OVA with 0.5 mg Al(OH)3 
adjuvant every 5 days for 4 weeks. Oral administration of crude or high molecular weight 
of F-fucoidan (200, 60 μg/day, respectively) was started on the 7th day before first 
injection of OVA. One day before the injection of OVA, blood samples were collected 
from the tail vein, and on the final day, whole blood was collected by cardiac puncture. 
The blood samples were centrifuged at 10,000 rpm for 10 min after incubation at room 
temperature for 1 h and at 4°C overnight for serum. The amount of total IgE, OVA-
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specific IgE and OVA-specific IgG1 were measured from serum by using ELISA kit (BD 
Biosciences, San Jose, CA, USA, DS Pharma Biomedical, Osaka, Japan, and Cayman 
Chemical, Ann Arbor, MI, USA, respectively). After sensitization by twice 
intraperitoneally injection of OVA, rectal temperature was measured every 10 min for 90 
min immediately following intravenous injection of OVA (2 μg/mouse) using a rectal 
thermometer for mice (AD-1687; A & D, Tokyo, Japan).  
 
5.2.4. Measurement of cytokine production from splenocytes 
Splenocytes were prepared from mice which were induced allergy by OVA and 
administrated F-fucoidan. To evaluate OVA-induced cytokine production, the hemolyzed 
splenocytes (5 × 106 cells/ml) were stimulated with 25 μg/ml OVA and cultured in 96 well 
microplate for 72 h. Culture supernatants were collected to measure the amount of 
cytokine using Mouse Th1/Th2 10plex Ready-to-Use FlowCytomix Kit (Affymetrix, 
Santa Clara, CA, USA) according to manufacturer’s protocol. 
 
5.2.5. Sampling of tissues, RNA isolation and real-time PCR 
IECs were prepared and the expression of galectin-9 and β-actin in IECs was measured 
as described in Chapter 2. 
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5.2.6. Statistical analysis 
Data were expressed as means ± the SE. Statistical analysis was performed by Tukey-
Kramer test. p ˂ 0.05 was considered statistically significant. 
 
 
5.3. Results 
5.3.1. The effect of F-fucoidan on increase of serum IgE and IgG1 contents induced by 
ovalbumin 
To confirm whether F-fucoidan affected the Th1/Th2 balance, the amount of serum IgE 
and IgG1 were measured. Oral administration of crude or high molecular weight of F-
fucoidan shows no changes in serum total IgE content increased by OVA injection (Fig. 
5.1.A). Moreover, the increase in OVA-specific IgE and IgG1 in serum at end of 
experiment was not suppressed by administration of crude or high molecular weight of 
F-fucoidan (Fig. 5.1.B, C). These data suggested that F-fucoidan from S. japonica could 
not modulate immune response, particularly Th2 dominant, in contrast with previous 
reports about fucoidan function [23-25,46]. 
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Figure 5.1. The effect of F-fucoidan on the increase in IgE and IgG1 induced by 
ovalbumin injection. 
Mice were administered crude or high molecular weight of F-fucoidan orally (200, 60 
𝜇g/day, respectively) and immunized with ovalbumin (OVA) as described in the Materials 
and Methods. (A) Amount of total IgE (𝜇g/ml) in serum collected from the tail vein 1 day 
before injection OVA was measured. Serum OVA-specific IgE (𝜇g/ml) (B) and OVA-
specific IgG1 (mg/ml) (C) content on the final day were measured. Values represent the 
means ± S.E. of 6–7 mice in each group. U.D. indicates under detection. 
 
5.3.2. The effect of F-fucoidan on ovalbumin-induced cytokine production 
To further evaluate systemic Th1/Th2 balance, cytokine production from splenocytes 
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which were prepared from OVA-induced allergy model mouse. Interferon (IFN)- and 
IL-4 were used as marker of typical Th1 and Th2 cytokines, respectively. When 
splenocytes were re-stimulated with OVA, splenocytes from mice induced allergy by 
OVA increased IL-4 production (Fig. 5.2.A) and decreased IFN-γ production (Fig. 5.2.B). 
Administration of crude or high molecular weight of F-fucoidan did not affect the increase 
of IL-4 and decrease of IFN-γ induced by OVA stimulation. 
 

Figure 5.2. The effect of F-fucoidan on cytokine production induced by ovalbumin 
injection. 
Mice were administered crude or high molecular weight of F-fucoidan orally (200, 60 
𝜇 g/day, respectively) and immunized with ovalbumin (OVA) as described in the 
Materials and Methods. Splenocytes (5 × 106 cells/ml) were prepared and re-stimulated 
by OVA (25 𝜇g/ml) as described in the Materials and Methods. Culture supernatants 
were collected and the amount of IL-4 (ng/ml) (A) and IFN-γ (ng/ml) (B) were measured. 
Different alphabet indicates a significant difference. Values represent the means ± S.E. of 
3 mice in each group.  
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5.3.3. The inhibitory effect of F-fucoidan on allergic symptom in OVA-induced allergy 
model 
It was demonstrated in Figs. 5.1. and 5.2. that F-fucoidan did not exhibit the immune 
modulatory effects. However, F-fucoidan can inhibit mast cell activation and following 
allergic symptom as shown in Chapter 2. Therefore, the author presumed that F-fucoidan 
could inhibit type I allergic symptom induced by OVA injection even though IgE and IgG1 
contents were no changes. Therefore, rectal temperature was measured after intravenous 
injection of OVA to evaluate the effect of F-fucoidan on allergic symptom. It has been 
reported that mast cell released chemical mediator such as histamine by mast cell 
activation and this mediator induced vessel permeability and vasodilatation [52]. 
Vasodilation has been known to induce hypotension, followed by decrease of body 
temperature. Thus, decrease of rectal temperature has been commonly used as a marker 
of systemic allergic symptom [49,53,54]. Rectal temperature decreased 5.6°C at 40 min 
after intravenous injection of OVA and resumed at 90 min after injection of OVA in the 
OVA-control group (Fig. 5.3). In contrast, its decrease in mice administrated crude or 
high molecular weight of F-fucoidan was moderate. Rectal temperature in mice 
administrated crude or high molecular weight of F-fucoidan decreased 3.8 and 3.7°C, 
respectively at 30 min after injection of OVA and almost resumed at 80 min after injection 
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of OVA (Fig. 5.3). This result indicated that F-fucoidan can inhibit allergic symptom 
without modulating Th1/Th2 balance. 
 
 
Figure 5.3. The effect of F-fucoidan on decrease of rectal temperature induced by 
ovalbumin injection. 
Mice were administered crude or high molecular weight of F-fucoidan orally (200, 60 
𝜇g/day, respectively) and immunized by intraperitoneal injection of ovalbumin (OVA) as 
described in the Materials and Methods. Rectal temperature was measured every 10 min 
for 90 min immediately following intravenous injection of OVA (2 μg/mouse). * p < 0.05, 
** p < 0.01, significantly different from the values of the group that was not administrated 
F-fucoidan and injected OVA at the same time point. Values represent the means ± S.E. 
of 4 mice in each group.  
 
5.3.4. Association between the anti-allergic effect of F-fucoidan in ovalbumin-induced 
allergy model and galectin-9 induction 
To confirm that the anti-allergic effect of F-fucoidan in OVA-induced allergy model was 
dependent on galectin-9, galectin-9 mRNA expression in IECs of mice after measurement 
of rectal temperature was determined. Galectin-9 mRNA expression in IECs of mice 
injected OVA without F-fucoidan did not show any change compared with IECs of OVA-
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noninjected mice (Fig. 5.4). In contrast, administration of crude or high molecular weight 
of F-fucoidan increased expression of galectin-9 mRNA in IECs (Fig. 5.4). This indicated 
that the inhibitory effect of F-fucoidan on the decrease of rectal temperature which 
induced by mast cell activation was due to galectin-9. 
 
 
Figure 5.4. Expression of galectin-9 mRNA in intestinal epithelial cells in ovalbumin-
induced allergy model. 
Mice were administered crude or high molecular weight of F-fucoidan orally (200, 60 
𝜇g/day, respectively) and immunized by intraperitoneal injection of ovalbumin (OVA) as 
described in the Materials and Methods. Galectin-9 mRNA expression in intestinal 
epithelial cells of mice after measurement of rectal temperature was measured. * p< 0.05, 
**p < 0.01, significantly different from the values of the group that was not injected OVA. 
Values represent the means ± S.E. of 4 mice in each group.  
 
 
5.4. Discussion 
It has been reported that fucoidan exhibits immune modulatory effects including 
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anti-allergic effect [23-25,46,55]. However, F-fucoidan from S. japonica exerted anti-
allergic property by inhibition of mast cell activation in dependent on galectin-9 as shown 
in Chapter 2. Galectin-9 has been reported not to affect serum IgE and IgG1 contents [27], 
suggesting that galectin-9 does not influence immune responses. The author presumed 
that F-fucoidan exhibits anti-allergic effect by inhibiting mast cell activation dependently 
on galectin-9 but not affecting immune systems. The effect of F-fucoidan in an animal 
model that allergy was induced by sensitization of antigen was investigated. F-fucoidan 
from S. japonica did not affect the increase in serum IgE and IgG1 contents (Fig. 5.1) and 
production of Th1 and Th2 cytokines (Fig. 5.2) induced by OVA. In contrast, F-fucoidan 
inhibited allergic symptoms which was caused by mast cell degranulation such as 
decrease of body temperature (Fig. 5.3). The effect of F-fucoidan was dependent on 
galectin-9 in OVA-induced allergy model (Fig. 5.4), as is the results in the PCA reaction 
in Chapter 2. These results suggested that F-fucoidan could inhibit mast cell activation 
but not polarization to Th2 which was previously reported as an effect of fucoidan [23-
25,46] and that F-fucoidan could suppress type I allergy even after sensitization by 
antigen.  
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CHAPTER 6 
 
General Discussion and Conclusion 
 
 It has been known that type I allergic symptoms are induced by increased IgE in 
blood and thereby mast cell activation. Therefore, there are mainly two therapeutic 
approaches in allergy that suppress polarization to Th2 and increase of IgE in blood, and 
that directly prevent mast cell activation [5]. Among the food factors having the anti-
allergic effect, dietary fiber and probiotic foods, which are barely absorbed into the body, 
have been frequently reported to exhibit the effect of the former [15-18,56]. In contrast, 
carotenoids, flavonoids, and other small components of food, which are absorbed into the 
body, have been reported to have the effect of the latter [12-14,57], although some of 
them also have the immune modulatory effects. Fucoidan, which is a dietary 
polysaccharide focused in this study, has mainly been reported to have the effect of the 
former [23-25,46], since it is poorly absorbed into the body [22,26]. However, in this 
study, it was elucidated that F-fucoidan (only high molecular weight of F-fucoidan) from 
S. japonica exhibited the inhibitory effect on mast cell activation through gut (Chapter 2, 
3). The inhibitory mechanism was a novel mechanism that F-fucoidan induced galectin-
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9 expression and secretion into blood, which has not been reported previously. This effect 
was shown by only fucoidan from S. japonica (Makombu) not by fucoidan from other sea 
algae (Chapter 4). Furthermore, in contrast with previous reports, it was eliminated that 
F-fucoidan from S. japonica inhibited allergic symptom induced by mast cell activation 
without affecting deflection to Th2 (Chapter 5).  
 The result that F-fucoidan inhibited ear edema and the decrease of rectal 
temperature which were caused by mast cell activation, but did not suppress the increase 
of serum IgE and IgG1 contents and the disproportion of Th1/Th2 balance (Chapter 2, 5) 
was consistent with a previous report that the exogenous galectin-9 could suppress ear 
swelling induced by IgE/antigen, although it did not affect the serum contents of IgE and 
IgG1 [27]. Besides, while it has been reported that mast cells expressed T-cell 
immunoglobulin and mucin-containing protein-3 (TIM-3), which is one of the major 
targets of galectin-9 [58,59], activation of TIM-3 on mast cells did not affect mast cell 
degranulation induced by IgE/antigen [59]. These reports and the results in this study 
suggested that galectin-9 induced by F-fucoidan interacted with IgE but not TIM-3 and 
prevented allergic symptoms. 
 In Chapter 2, it was demonstrated that 200 μg of crude F-fucoidan could inhibit 
type I allergic symptom induced by mast cell activation. It was clarified that crude F-
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fucoidan was contained 5% in dried S. japonica as shown in Chapter 4. Therefore, this 
effective dose is converted to 12 g of dried S. japonica in 60 kg of human body weight. 
This dose is the amount which can be eaten effortlessly. In addition, it was elucidated that 
high molecular weight of F-fucoidan exhibited the anti-allergic effect through induction 
galectin-9 but not low molecular weight of F-fucoidan (Chapter 3). This suggested that S. 
japonica was taken unheated S. japonica for getting the anti-allergic effect of F-fucoidan. 
 Our laboratory previously reported that oral administration of F-fucoidan was 
not completely absorbed into the body and was excreted in the feces [22]. Therefore, it 
was assumed that F-fucoidan interacts with factors on cells in small intestine and 
promotes the expression and secretion of galectin-9. Fucoidan has been reported to 
interact with several lectins [60-63], and IECs express various lectins [64-66]. Thus, 
fucoidan could be recognized through one of the lectins on IECs. In addition, DCs have 
been reported to pass their dendrites between IECs and have DC-specific intracellular 
adhesion molecule 3-grabbing non-integrin (DC-SIGN), which recognizes fucose [67]. It 
has been known that DCs can protrude dendrites to the luminal side, and DC-SIGN is 
also expressed on protruding dendrites [68]. Thus, F-fucoidan might be recognized by 
DCs using intraepithelial dendrites but not by IECs. However, the receptor that recognizes 
F-fucoidan has not yet been identified, although there are some candidates. 
48  General Discussion and Conclusion 
 
 
 In the future, to clarify further mechanism of the effect of F-fucoidan, the culture 
system mimicked in vivo is needed. Our laboratory previously developed the co-culture 
system with Caco-2 cells (apical side) as IECs and RBL-2H3 cells (basolateral side) as 
mast cells [69]. Although this system could evaluate the anti-allergic effect of prebiotics 
or polyphenols, the effect of F-fucoidan in vivo was not mimicked. It has been reported 
that Caco-2 cells did not express galectin-9 generally but Caco-2 cells express galectin-9 
only when Caco-2 cells were induced differentiation to M cells [70]. It was estimated that 
the effect of F-fucoidan in vivo was not observed in vitro co-culture system, since the 
effect of F-fucoidan in vivo was dependent on galectin-9. T84 and HT-29 cells, which are 
known as human IEC cell lines, have been reported to express galectin-9 and secret 
galectin-9 into basolateral side [71]. Therefore, the construction of a novel co-culture 
system using these cell lines is needed. If a novel co-culture system is constructed, further 
mechanisms of the anti-allergic effect of F-fucoidan such as receptor for F-fucoidan and 
following signaling will be clarified. 
 The author concluded that oral treatment with F-fucoidan from S. japonica 
prevented type I allergy through the inhibition of mast cell activation but not the inhibition 
of Th2 polarization. This anti-allergic mechanism of F-fucoidan suggested that F-
fucoidan may be an effective inhibitor that can prevent symptoms in type I allergic 
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patients even after sensitization to allergen. 
50  References 
 
 
REFERENCES 
 
1. Masoli M., Fabian D., Holt S., and Beasley R. (2004) The global burden of asthma: 
executive summary of the GINA Dissemination Committee report. Allergy. 59, 469-
478. 
2. Asher M.I., Montefort S., Bjӧrkstén B., Lai C.K., Strachan D.P., Wiland S.K., and 
Williams H. (2006) Worldwide time trends in the prevalence of symptoms 
of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC 
Phases One and Three repeat multicountry cross-sectional surveys. 
Lancet. 368, 733-743. 
3. Graham-Rowe D. (2011) Lifestyle: When allergies go west. Nature. 479, S2-S4. 
4. Del Prete G., Maggi E., Parronchi P., Chrétien I., Tiri A., Macchia D., Ricci M., 
Banchereau J., De Vries J., and Romagnani S. (1988) IL-4 is an essential factor for 
the IgE synthesis induced in vitro by human T cell clones and their supernatants. J. 
Immunol. 140, 4193-4198. 
5. Holgate S.T., and Polosa R. (2008) Treatment strategies for allergy and asthma. Nat. 
Rev. Immunol. 8, 218-230. 
References  51 
 
 
 
6. Schley P.D., and Field C.J. (2002) The immune-enhancing effects of dietary fibres 
and prebiotics. Br. J. Nutr. 87, S221-S230. 
7. Volman J.J., Ramakers J.D., and Plat J. (2008) Dietary modulation of immune 
function by β-glucans. Physiol. Behev. 94, 276-284. 
8. Rein D., Paglieroni T.G., Pearson D.A., Wun T., Schimitz H.H., Gosselin R., and 
Keen C.L. (2000) Cocoa and wine polyphenols modulate platelet activation and 
function. J. Nutr. 130, 2120S-2126S. 
9. Vucevic D., Melliou E., Vasiliji S., Gasic S., Ivanovski P., Chinou I., and Colic M. 
(2007) Fatty acids isolated from royal jelly modulate dendritic cell-mediated immune 
response in vitro. Int. Immunopharmacol. 7, 1211-1220. 
10. Galdeano C.M., and Perdigón G. (2006) The probiotic bacterium Lactobacillus casei 
induces activation of the gut mucosal immune system through innate immunity. Clin. 
Vaccine Immunol. 13, 219-226. 
11. Maslowski K.M., and Mackay C.R. (2011) Diet, gut microbiota and immune 
responses. Nat. Immunol. 12, 5-9. 
12. Wu Y.Q., Zhou C.H., Tao J., and Li S.N. (2006) Antagonistic effects of nobiletin, a 
polymethoxyflavonoid, on eosinophilic airway inflammation of asthmatic rats and 
relevant mechanisms. Life Sci. 78, 2689-2696.  
52  References 
 
 
13. Kim J.W., Lee J.H., Hwang B.Y., Mun S.H., Ko N.Y., Kim do K., Kim B., Kim H.S., 
Kim Y.M., and Choi W.S. (2009) Morin inhibits Fyn kinase in mast cells and IgE-
mediated type I hypersensitivity response in vivo. Biochem. Pharmacol. 77, 1506-
1512. 
14. Wang X., Ma D.W., Kang J.X., and Kulka M. (2015) n-3 Polyunsaturated fatty acids 
inhibit Fc ε receptor I-mediated mast cell activation. J. Nutr. Biochem. 26, 1580-
1588.  
15. Murosaki S., Yamamoto Y., Ito K., Inokuchi T., Kusaka H., Ikeda H., and Yoshikai Y. 
(1998) Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-
specific IgE production by stimulation of IL-12 production in mice. J Allergy Clin 
Immunol. 102, 57-64. 
16. Shida K., Takahashi R., Iwadate E., Takamizawa K., Yasui H., Sato T., Habu S., 
Hachimura S., and Kaminogawa S. (2002) Lactobacillus casei strain Shirota 
suppresses serum immunoglobulin E and immunoglobulin G1 responses and 
systemic anaphylaxis in a food allergy model. Clin. Exp. Allergy. 32, 563-570. 
17. Lee J., Bang J., and Woo H.J. (2013) Immunomodulatory and anti-allergic effects of 
orally administered Lactobacillus species in ovalbumin-sensitized mice. J. Microbiol. 
Biotechnol. 23, 724-730. 
References  53 
 
 
 
18. Ramberg J.E., Nelson E.D., and Sinnott R.A. (2010) Immunomodulatory dietary 
polysaccharides: a systematic review of the literature. Nutr. J. 9, 54 
19. Li B., Lu F., Wei X., and Zhao R. (2008) Fucoidan: structure and bioactivity. 
Molecules. 13, 1671-1695. 
20. Synytsya A., Kim W.J., Kim S.M., Pohl R., Synytsya A., Kvasnička F., Čopíková J., 
and Park Y. (2010) Structure and antitumour activity of fucoidan isolated from 
sporophyll of Korean brown seaweed Undaria pinnatifida. Carbohydr. Polym. 81, 
41-48. 
21. Athukorala Y., Jung W.K., Vasanthan T., and Jeon Y.J. (2006) An anticoagulative 
polysaccharide from an enzymatic hydrolysate of Ecklonia cava. Carbohydr. Polym. 
66, 184–191. 
22. Ren R., Azuma Y., Ojima T., Hashimoto T., Mizuno M., Nishitani Y., Yoshida M., 
Azuma T., and Kanazawa K. (2013) Modulation of platelet aggregation-related 
eicosanoid production by dietary F-fucoidan from brown alga Laminaria japonica in 
human subjects. Br. J. Nutr. 110, 880-890.  
23. Vo T.S., Ngo D.H., Kang K.H., Jung W.K., and Kim S.K. (2015) The beneficial 
properties of marine polysaccharides in alleviation of allergic responses. Mol. Nutr. 
Food Res. 59, 129-138.  
54  References 
 
 
24. Oomizu S., Yanase Y., Suzuki H., Kameyoshi Y., and Hide M. (2006) Fucoidan 
prevents Cε germline transcription and NFκB p52 translocation for IgE production 
in B cells. Biochem. Biophys. Res. Commun. 350, 501-507. 
25. Yanase Y., Hiragun T., Uchida K., Ishii K., Oomizu S., Suzuki H., Mihara S., 
Iwamoto K., Matsuo H., Onishi N., Kameyoshi Y., and Hide M. (2009) Peritoneal 
injection of fucoidan suppresses the increase of plasma IgE induced by OVA-
sensitization. Biochem. Biophys. Res. Commun. 387, 435-439. 
26. Tokita Y., Nakajima K., Mochida H., Iha M., and Nagamine T. (2010) Development 
of a fucoidan-specific antibody and measurement of fucoidan in serum and urine by 
sandwich ELISA. Biosci Biotechnol Biochem. 74, 350-357. 
27. Niki T., Tsutsui S., Hirose S., Aradono S., Sugimoto Y., Takeshita K., Nishi N., and 
Hirashima M. (2009) Galectin-9 is a high affinity IgE-binding lectin with anti-
allergic effect by blocking IgE-Antigen complex formation. J. Biol. Chem. 284, 
32344-32352. 
28. Seki M., Oomizu S., Sakata K.M., Sakata A., Arikawa T., Watanabe K., Ito K., 
Takeshita K., Niki T., Saita N., Nishi N., Yamauchi A., Katoh S., Matsukawa A., 
Kuchroo V., and Hirashima M. (2008) Galectin-9 suppresses the generation of Th17, 
References  55 
 
 
 
promotes the induction of regulatory T cells, and regulates experimental autoimmune 
arthritis. Clin. Immunol. 127, 78-88. 
29. Dai S.Y., Nakagawa R., Itoh A., Murakami H., Kashio Y., Abe H., Katoh S., Kontani 
K., Kihara M., Zhang S.L., Hata T., Nakamura T., Yamauchi A., and Hirashima M. 
(2005) Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. 
Immunol. 175, 2974-2981 
30. Sziksz E., Kozma G.T., Pállinger E., Komlósi Z.I., Adori C., Kovács L., Szebeni B., 
Rusai K., Losonczy G., Szabó A., and Vannay A. (2010) Galectin-9 in allergic airway 
inflammation and hyper-responsiveness in mice. Int. Arch. Allergy Immunol. 151, 
308-317. 
31. Chen X., Song C.H., Liu Z.Q., Feng B.S., Zheng P.Y., Li P., In S.H., Tang S.G., and 
Yang P.C. (2011) Intestinal epithelial cells express galectin-9 in patients with food 
allergy that plays a critical role in sustaining allergic status in mouse intestine. Allergy. 
66, 1038-1046. 
32. Nakajima R., Miyagaki T., Oka T., Nakao M., Kawaguchi M., Suga H., Morimura S., 
Kai H., Asano Y., Tada Y., Kadono T., Sato S., and Sugaya M. (2015) Elevated serum 
galectin-9 levels in patients with atopic dermatitis. J Dermatol. 42, 723-726. 
56  References 
 
 
33. Katoh S., Ishii N., Nobumoto A., Takeshita K., Dai S.Y., Shinonaga R., Niki T., Nishi 
N., Tominaga A., Yamauchi A., and Hirashima M. (2007) Galectin-9 inhibits CD44-
hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. 
Respir. Crit. Care Med. 176, 27-35. 
34. de Kivit S., Saeland E., Kranevend A.D., van de Kant H.J., Schouten B., van Esch 
B.C., Knol J., Sprikkelman A.B., van der Aa L.B., Knippels L.M., Garssen J., van 
Kooyk Y., and Willemsen L.E. (2012) Galectin-9 induced by dietary synbiotics is 
involved in suppression of allergic symptoms in mice and humans. Allergy. 67, 343-
352. 
35. Vo T.S., and Kim S.K. (2014) Marine-derived polysaccharides for regulation of 
allergic responses. Adv. Food Nutr. Res. 73, 1-13. 
36. Madireddi S., Eun S.Y., Lee S.W., Nemčovičová I., Mehta A.K., Zajonc D.M., Nishi 
N., Niki T., Hirashima M., and Croft M. (2014) Galectin-9 controls the therapeutic 
activity of 4-1BB-targeting antibodies. J. Exp. Med. 211, 1433-1448. 
37. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J. Zheng X.X., 
Strom T.B., and Kuchroo V.K. (2005) The Tim-3 ligand galectin-9 negatively 
regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252. 
References  57 
 
 
 
38. Zhang Q., Laun H., Wang L., He F., Zhou H., Xu X., Li X., Xu Q., Niki T., Hirashima 
M., Xu G., Lv Y., and Yuan J. (2014) Galectin-9 ameliorates anti-GBM 
glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice. Am. J. 
Physiol. Renal. Physiol. 306, F822-F832. 
39. Chou F.C., Shieh S.J., and Sytwu H.K. (2009) Attenuation of Th1 response through 
galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD 
mice. Eur. J. Immunol. 39, 2403-3411. 
40. Laurienzo P. (2010) Marine polysaccharides in pharmaceutical applications: an 
overview. Mar. Drugs. 8, 2435-2465. 
41. d’Ayala G.G., Malinconico M., and Laurienzo P. (2008) Marine derived 
polysaccharides for biomedical applications: chemical modification approaches. 
Molecules. 13, 2069-2106. 
42. Jeong H.J., Lee S.A., Moon P.D., Na H.J., Park R.K., Um J.Y., Kim H.M., and Hong 
S.H. (2006) Alginic acid has anti-anaphylactic effects and inhibits inflammatory 
cytokine expression via suppression of nuclear factor-κB activation. Clin. Exp. 
Allergy. 36, 785-794. 
58  References 
 
 
43. Uno T., Hattori M., and Yoshida T. (2006) Oral administration of alginic acid 
oligosaccharide suppresses IgE production and inhibits the induction of oral 
tolerance. Biosci. Biotechnol. Biochem. 70, 3054-3057. 
44. Katayama S., Nishio T., Kishimura H., and Saeki H. (2012) Immunomodulatory 
properties of highly viscous polysaccharide extract from the gagome alga 
(Kjellmaniella crassifolia). Plant Foods Hum. Nutr. 67, 76-81. 
45. Berteau O., and Mulloy B. (2003) Sulfated fucans, fresh perspectives: structures, 
functions, and biological properties of sulfated fucans and an overview of enzymes 
active toward this class of polysaccharide. Glycobiology. 13, 29R-40R. 
46. Maruyama H., Tamauchi H., Hashimoto M., and Nakano T. (2005) Suppression of 
Th2 immune responses by mekabu fucoidan from Undaria pinnatifida sporophylls. 
Int. Arch. Allergy Immunol. 137, 289-294. 
47. Nasu T., Fukuda Y., Nagahira K., Kawashima H., Noguchi C., and Nakanishi T. 
(1997) Fucoidin, a potent inhibitor of L-selectin function, reduces contact 
hypersensitivity reaction in mice. Immunol. Lett. 59, 47-51. 
48. Ngaoka M., Shibata H., Kimura-Takagi I., Hashimoto S., Kimura K., Makino T., 
Aiyama R., Ueyama S., and Yokokura T. (1999) Structural study of fucoidan from 
Cladosiphon okamuranus TOKIDA. Glycoconj. J. 16, 19-26. 
References  59 
 
 
 
49. Brandt E.B., Strait R.T., Hershko D., Wang Q., Muntel E.E., Scribner T.A., 
Zimmermann N., Finkelman F.D., and Rothenberg M.E. (2003) Mast cells are 
required for experimental oral allergen-induced diarrhea. J. Clin. Invest. 112, 1666-
1677. 
50. Hsieh K.Y., Tsai C.C., Wu C.H., and Lin R.H. (2003) Epicutaneous exposure to 
protein antigen and food allergy. Clin. Exp. Allergy. 33, 1067-1075. 
51. Wang Y., Miwa T., Ducka-Kokalari B., Redai I.G., Sato S., Gullipalli D., Zangrilli 
J.G., Haczku A., and Song W.C. (2015) Properdin contributes to allergic airway 
inflammation through lacal C3a generation. J. Immunol. 195, 1171-1181. 
52. White M.V. (1990) The role of histamine in allergic diseases. J. Allergy Clin. 
Immunol. 86, 599-605. 
53. Taketomi Y., Ueno N., Kojima T., Sato H., Murase R., Yamamoto K., Tanaka S., 
Sakanaka M., Nakamura M., Nishito Y., Kawana M., Kambe N., Ikeda K., Taguchi 
R., Nakamizo S., Kabashima K., Gelb M.H., Arita M., Yokomizo T., Nakamura M., 
Watanabe K., Hirai H., Nakamura M., Okayama Y., Ra C., Aritake K., Urade Y., 
Morimoto K., Sugimoto Y., Shimizu T., Narumiya S., Hara S., and Murakami M. 
(2013) Mast cell maturation is driven via a group III phospholipase A2-prostaglandin 
D2-DP1 receptor paracrine axis. Nat. Immunol. 14, 554-563. 
60  References 
 
 
54. Hox V., Desai A., Bandara G., Gilfillan A.M., Metcalfe D.D., and Olivera A. (2015) 
Estrogen increases the severity of anaphylaxis in female mice through enhanced 
endothelial nitric oxide synthase expression and nitric oxide production. J. Allergy 
Clin. Immunol. 135, 729-736. 
55. Negishi H., Mori M., Mori H., and Yamori Y. (2013) Supplementation of elderly 
Japanese men and women with fucoidan from seaweed increases immune responses 
to seasonal influenza vaccination. J. Nutr. 143, 1794-1798. 
56. Bouike G., Nishitani Y., Shiomi H., Yoshida M., Azuma T., Hashimoto T., Kanazawa 
K., and Mizuno M. (2011) Oral treatment with extract of Agaricus blazei Murill 
enhanced Th1 response through intestinal epithelial cells and suppressed OVA-
sensitized allergy in mice. Evid. Based Complement. Alternat. Med. Article ID 
532180. 
57. Hagenlocher Y., and Lorentz A. (2015) Immunomodulation of mast cells by nutrients. 
Mol. Immunol. 63, 25-31. 
58. Nakae S., Iikura M., Suto H., Akiba H., Umetsu D.T., Dekruyff R.H., Saito H., and 
Galli S.J. (2007) TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast 
cells. Blood. 110, 2565-2568. 
References  61 
 
 
 
59. Wiener Z., Kohalmi B., Pocza P., Jeager J., Tolgyesi G., Toth S., Gorbe E., Papp Z., 
and Falus A. (2007) TIM-3 is expressed in melanoma cells and is upregulated in 
TGF-beta stimulated mast cells. J. Invest. Dermatol. 127, 906-914. 
60. Bevilacqua M.P., and Nelson R.M. (1993) Selectins. J. Clin. Invest. 91, 379-387. 
61. Francischetti I.M., Ma D., Andersen J.F., and Ribeiro J.M. (2014) Evidence for a 
lectin specific for sulfated glycans in the salivary gland of the malaria vector, 
Anopheles gambiae. PLoS One. 9, e107295. 
62. Gange C.T., Quinn J.M., Zhou H., Kartsogiannis V., Gillespie M.T., and Ng K.W. 
(2004) Characterization of sugar binding by osteoclast inhibitory lectin. J. Biol. 
Chem. 279, 29043-29049. 
63. Manne B.K., Getz T.M., Hughes C.E., Alshehri O., Dangelmaier C., Naik U.P., 
Watson S.P., and Kunapuli S.P. (2013) Fucoidan is a novel platelet agonist for the C-
type lectin-like receptor 2 (CLEC-2). J. Biol. Chem. 288, 7717-7726. 
64. Cohen-Kedar S., Baram L., Elad H., Brazowski E., Guzner-Gur H., and Dotan I. 
(2014) Human intestinal epithelial cells respond to β-glucans via Dectin-1 and Syk. 
Eur. J. Immunol. 44, 3729-3740. 
62  References 
 
 
65. Moucadel V., Soubeyran P., Vasseur S., Dusetti N.J., Dagorn J.C., and Iovanna J.L. 
(2001) Cdx1 promotes cellular growth of epithelial intestinal cells through induction 
of the secretory protein PAP I. Eur. J. Cell Biol. 80, 156-163. 
66. Akiyama Y., Oshima K., Shin K., Wakabayashi H., Abe F., Nadano D., and Matsuda 
T. (2013) Intracellular retention and subsequent release of bovine milk lactoferrin 
taken up by human enterocyte-like cell lines, Caco-2, C2BBe1 and HT-29. Biosci. 
Biotechnol. Biochem. 77, 1023-1029. 
67. Geijtenbeek T.B.H., and Gringhuis S.I. (2009) Signalling through C-type lectin 
receptors: shaping immune responses. Nat. Rev. Immunol. 9, 465-479. 
68. Bron P.A., van Baarlen P., and Kleerebezem M. (2011) Emerging molecular insights 
into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. 
Microbiol. 10, 66-78. 
69. Yokoyama Y. (2015) A novel in vitro co-culture model constructed by Caco-2/RBL-
2H3 cells to evaluate anti-allergic food factors. The master thesis. 
70. Pielage J.F., Cichon C., Greune L., Hirashima M., Kucharzik K., and Schmidt M.A. 
(2007) Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface 
marker molecule for human follicle-associated epithelia and M cell-like cells. Int. J. 
Biochem. Cell Biol. 39, 1886-1901. 
References  63 
 
 
 
71. de Kivit S., Kraneveld A.D., Knippels L.M., van Kooyk Y., Garssen J., and 
Willemsen L.E. (2013) Intestinal epithelium-derived galectin-9 is involved in the 
immunomodulating effects of nondigestible oligosaccharides. J. Innate Immun. 5, 
625-638. 
  
Acknowledgments 
 
 
 
ACKNOWLEDGMENTS 
 
 The author would like to express her grateful thanks to Dr. Masashi Mizuno, 
Professor of Kobe University, for kind guidance and various suggestions throughout the 
course of this study, and special thanks to Dr. Takashi Hashimoto, Associate Professor of 
Kobe University, for all during the course. The author is deeply grateful to Drs. Takeshi 
Azuma and Ken-ichi Yoshida, Professor of Kobe University for their helpful advice and 
helpful advice and useful comments. The author also wishes to express her sincere 
gratitude to Dr. Takao Ojima, Professor of Hokkaido University, Dr. Kazuki Kanazawa, 
Emeritus Professor of Kobe University, and Dr. Yoshiko Aihara, Assistant Professor of 
Kobe University, for their kind guidance and various suggestions. 
 It is my pleasure to acknowledge the support and encouragement of Miss Yuki 
Yokoyama, and Sae Yamashita, and the other members of Laboratory of Food and 
Nutritional Chemistry, Graduate School of Agricultural Science, Kobe University. 
 The author is also grateful to her parents for their great encouragement and 
support. 
 
